| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/12/2012 | CN102657866A Cancer prevention and fighting capsules |
| 09/12/2012 | CN102657865A Method for conveying proteins or antigens to mammal intestinal tract in targeted way by using transgenic coccidian |
| 09/12/2012 | CN102657864A Immune adjuvant of foot-and-mouth disease vaccine and application of immune adjuvant |
| 09/12/2012 | CN102657863A Method for preparing and storing low temperature particles for active medicament |
| 09/12/2012 | CN102657862A Herpes simplex virus type 2 (HSV-2) genetic recombinant attenuated live vaccine and preparation method thereof |
| 09/12/2012 | CN102657861A Herpes simplex virus I-type gene recombinant attenuated live vaccine and preparation method thereof |
| 09/12/2012 | CN102657860A Canine parvovirus propolis inactivated vaccine and preparation method thereof |
| 09/12/2012 | CN102657859A Method for producing avian influenza vaccine by using cells cultured by spherical microcarrier bioreactor |
| 09/12/2012 | CN102657858A Method for preparing enterovirus vaccines |
| 09/12/2012 | CN102657857A Method for preparing intestinal virus vaccine by using gerbil kidney cell |
| 09/12/2012 | CN102657856A Bacterium-delivered double cross protection vaccine |
| 09/12/2012 | CN102657855A Immunogenic composition for use in vaccination against staphylococcei |
| 09/12/2012 | CN102657854A Multi-epitope vaccine YL66 and application of preparing vaccine for treating tumour |
| 09/12/2012 | CN102657853A Preparation and application of tumor specific killer cells serving as source of initial thymus (T) cells |
| 09/12/2012 | CN102657599A Method for preparing bioactive injectable hydrogel materials for oncotherapy |
| 09/12/2012 | CN102178958B MBD2-mTEM fused DNA vaccine and preparation method and application thereof |
| 09/12/2012 | CN102174444B Method for proliferating H9 subtype avian influenza virus and pasteurella in chick embryos |
| 09/12/2012 | CN102049044B Calcium supplementing composition preparation for improving calcium absorption |
| 09/12/2012 | CN101897960B hNgR-Fc fusion protein vaccine for promoting regeneration and functional recovery of central nerves |
| 09/12/2012 | CN101863970B Anti-Pf332-DBL region monoclonal antibody capable of restraining invasion of plasmodiumfalciparum |
| 09/12/2012 | CN101773668B Antivirus associated protein and application thereof |
| 09/12/2012 | CN101579522B Novel peptide-based vaccine used for domestic animal and preparation method thereof |
| 09/12/2012 | CN101007851B Chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen |
| 09/11/2012 | US8263757 Promiscuous HER-2/Neu CD4 T cell epitopes |
| 09/11/2012 | US8263748 Lyophilized formulations of engineered anti-IL-23p19 antibodies |
| 09/11/2012 | US8263747 Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| 09/11/2012 | US8263746 Anti-CD38 human antibodies and uses thereof |
| 09/11/2012 | US8263744 Binding proteins that bind to EpCAM linked to an effector molecule |
| 09/11/2012 | US8263561 Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent |
| 09/11/2012 | US8263559 Feline granulocyte macrophage colony stimulating factor proteins |
| 09/11/2012 | US8263558 Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins |
| 09/11/2012 | US8263394 Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides, and uses thereof |
| 09/11/2012 | US8263363 Chimeric vaccine for Haemophilus influenzae-induced disease |
| 09/11/2012 | US8263326 Compounds and methods for modulating activation of NF-κB |
| 09/11/2012 | US8263092 Alphavirus replicon particles as immunological adjuvants |
| 09/11/2012 | US8263091 Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
| 09/11/2012 | US8263090 Major allergen Phl p 1 comprising reduced immunoglobulin reactivity for use in treating grass pollen allergies; immunotherapy |
| 09/11/2012 | US8263089 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 09/11/2012 | US8263088 Clostridial toxin NetB |
| 09/11/2012 | US8263087 Compositions and methods for vaccinating against HSV-2 |
| 09/11/2012 | US8263086 SlpA as a tool for recombinant protein and enzyme technology |
| 09/11/2012 | US8263085 Gammaretrovirus associated with cancer |
| 09/11/2012 | US8263084 Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| 09/11/2012 | US8263083 Combination therapy with antibody-drug conjugates |
| 09/11/2012 | US8263082 Chemically programmable immunity |
| 09/11/2012 | US8263081 Antibody-light fusion products for cancer therapeutics |
| 09/11/2012 | US8263080 Use of agonists and antagonists of IL-23 in the treatment of viral infection |
| 09/11/2012 | US8263079 Antibodies against CSF-1R |
| 09/11/2012 | US8263078 Antibodies against flagellin and uses thereof |
| 09/11/2012 | US8263077 Cell growth inhibitors containing anti-glypican 3 antibody |
| 09/11/2012 | US8263076 Anti-inflammatory dAb |
| 09/11/2012 | US8263075 Antibody molecule for human GM-CSF receptor alpha |
| 09/11/2012 | US8263074 Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
| 09/11/2012 | US8263073 Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof |
| 09/11/2012 | US8263072 ADAMTS4 as a blood biomarker and therapeutic target for chronic renal failure |
| 09/11/2012 | US8263071 Protein involved in ovarian cancer |
| 09/11/2012 | US8263070 Using immunoglobulin specific to receptor for OX-2 membrane glycoprotein as diagnostic and therapeutic tool for treatment and prevention of asthma, infection, allergies, skin and cell proliferative disorders |
| 09/11/2012 | US8263066 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| 09/11/2012 | US8263041 Antigen associated with the neovasculature of tumour metastases |
| 09/11/2012 | CA2635352C Stabilized antibody formulation |
| 09/11/2012 | CA2547032C Vaccine comprising an antigen conjugated to low valency anti-cd40 or anti-cd28 antibodies |
| 09/11/2012 | CA2544920C Method for the treatment of multiple sclerosis by inhibiting il-17 activity |
| 09/11/2012 | CA2530233C Purification of her-2 variants |
| 09/11/2012 | CA2519112C Optimized expression of hpv 31 l1 in yeast |
| 09/11/2012 | CA2510180C Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
| 09/11/2012 | CA2491864C Super humanized antibodies |
| 09/11/2012 | CA2491726C Feline infectious peritonitis vaccine |
| 09/11/2012 | CA2476403C Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors |
| 09/11/2012 | CA2451577C Gene delivery vectors with cell type specificity for mesenchymal stem cells |
| 09/11/2012 | CA2448123C Taci-immunoglobulin fusion proteins |
| 09/11/2012 | CA2442865C Vaccine composition |
| 09/11/2012 | CA2428027C Yeast derived vaccine against ipnv |
| 09/11/2012 | CA2395291C Five-helix protein |
| 09/11/2012 | CA2257247C Novel protein binding to osteoclastogenesis inhibitory factor and process for producing the same |
| 09/11/2012 | CA2254082C Metastatic colorectal cancer vaccine |
| 09/07/2012 | WO2012119077A1 Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
| 09/07/2012 | WO2012118930A2 Stable colloidal gold nanoparticles with controllable surface modification and functionalization |
| 09/07/2012 | WO2012118863A1 Therapies that target autoimmunity for treating glaucoma and optic neuropathy |
| 09/07/2012 | WO2012118857A2 Immunologically modified carbon nanotubes for cancer treatment |
| 09/07/2012 | WO2012118833A2 Identificationof c3 complement molecule at the site of injury to blood vessels in the retina of oxygen exposed animals |
| 09/07/2012 | WO2012118813A2 Anti-il-6 receptor antibodies and methods of use |
| 09/07/2012 | WO2012118632A1 Substituted quinoline compounds and methods of use |
| 09/07/2012 | WO2012118559A2 Tetravalent and mixed head bivalent dengue vaccine |
| 09/07/2012 | WO2012118547A1 Novel modulators and methods of use |
| 09/07/2012 | WO2012118388A1 Peptide-lipid constructs and their use in a fc-function assay |
| 09/07/2012 | WO2012118042A1 Medicinal agent for inhibiting metastasis of malignant tumor |
| 09/07/2012 | WO2012117532A1 Cancer inhibiting agent, antibody production enhancing agent, and therapeutic agent for hepatitis |
| 09/07/2012 | WO2012117377A1 Combination vaccines with lower doses of antigen and/or adjuvant |
| 09/07/2012 | WO2012117323A1 Therapeutic cancer vaccine |
| 09/07/2012 | WO2012117067A1 Antagonistic dr3 ligands |
| 09/07/2012 | WO2012117045A1 Infectious bronchitis virus (ibv) spike protein as subunit vaccine |
| 09/07/2012 | WO2012116811A1 Vaccination in elderly patients |
| 09/07/2012 | WO2012116810A1 Vaccination in newborns and infants |
| 09/07/2012 | WO2012116715A1 Vaccination in newborns and infants |
| 09/07/2012 | WO2012116714A1 Vaccination in elderly patients |
| 09/07/2012 | WO2012116595A1 Tumor necrosis factor-α humanized antibody |
| 09/07/2012 | WO2012096960A3 Stem cell factor inhibitor |
| 09/07/2012 | WO2012092469A3 Clostridium difficile antigens |
| 09/07/2012 | WO2012088290A3 Tri-variable domain binding proteins and uses thereof |
| 09/07/2012 | WO2012061637A3 Hsv-1 epitopes and methods for using same |